<DOC>
	<DOCNO>NCT02384733</DOCNO>
	<brief_summary>The purpose study investigate difference late radiation morbidity hypofractionated normofractionated loco-regional breast irradiation irrespective mastectomy lumpectomy . In patient candidate boost , boost provide simultaneous integrated boost .</brief_summary>
	<brief_title>Hypofractionated Loco-regional Adjuvant Radiation Therapy Breast Cancer Combined With Simultaneous Integrated Boost</brief_title>
	<detailed_description>The randomization 50 Gy / 25 fraction 40 Gy/15 fraction , 5 fraction weekly . In patient treat boost 2 dose level accept : 16 Gy/8 fraction 10 Gy/5 fraction . These boost treatment provide simultaneous integrated boost , overall treatment time general shorten 5 day . Thus dose level boost patient : 63 Gy / 51.52 Gy / 28 fraction , 57 Gy / 50 Gy / 25 fraction , 52.2 Gy / 42.3 Gy / 18 fraction , 45.75 Gy / 40 Gy / 15 fraction . The primary endpoint arm lymphedema 3 year radiation therapy , late radiation morbidity also evaluate along recurrence site recurrence . Follow morbidity continue 10 year . The hypothesis woman operate early breast cancer indication loco-regional radiation therapy offer moderately hypofractionated therapy without develop late radiation induce morbidity compare normofractionated radiation therapy .</detailed_description>
	<mesh_term>Lymphedema</mesh_term>
	<criteria>Operated early nodepositive breast cancer indication locoregional breast radiotherapy Previous radiotherapy chest wall , pregnant/lactating , comorbidity may hinder 10 year follow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Radiation induce morbidity , recurrence</keyword>
</DOC>